Alice Melão,  —

Latest results from the long-term extension of a Phase 1b study assessing increasing and fixed doses of aducanumab continue to show its potential as a therapy for early or mild Alzheimer’s disease. Similar to previous interim analyses, data collected for up to 48 months reveal that the investigative…

Two recent studies highlight the relationship between age and dementia, one finding that people with dementia survive an average of six years after their diagnosis, regardless of how old they are, and another reporting that the prevalence of dementia increases with age, even in the oldest population. Data from…

Neurotrope’s investigational compound Bryostatin-1 showed evidence of sustained improvement in cognition compared to placebo in patients with moderate-to-severe Alzheimer’s disease, according to additional results from a Phase 2 clinical trial. This beneficial effect was sustained for at least four weeks upon ending treatment and was even more pronounced in…

Biohaven Pharmaceuticals has enrolled the first patient in its Phase 2/3 clinical trial investigating the potential of trigriluzole as a treatment for patients with mild to moderate Alzheimer’s disease. The study, which is currently recruiting, is being conducted in collaboration with the Alzheimer’s Disease Cooperative Study (ADCS)…

The latest clinical data from Genentech on crenezumab and gantenerumab demonstrate the investigational therapies’ potential to reduce amyloid aggregates in Alzheimer’s disease patients. Trial results were discussed in several presentations at the 2018 Alzheimer’s Association International Conference (AAIC), recently held in Chicago. “The range of data that…

Results of a first, large-scale study into the prevalence of dementia among lesbian, gay, and bisexual older adults in the U.S. were recently announced at an Alzheimer’s conference — and while findings largely mirrored the general population, they also underscored a patient population that is vulnerable and with special challenges.

The latest data from a Phase 2 trial (study 201) demonstrates that BAN2401 can slow cognitive decline, providing additional evidence of its potential as a disease-modifying therapy for Alzheimer’s disease, according to Eisai and Biogen, which are jointly developing the investigative therapy. BAN2401 is an engineered antibody…

Low-intensity pulsed ultrasound (LIPUS) therapy applied to the whole brain can be an effective, non-invasive strategy to reduce cognitive impairment associated with vascular dementia and Alzheimer’s disease, according to results from a mouse study. The study, “Whole-brain low-intensity pulsed ultrasound therapy markedly improves cognitive dysfunctions in…

The process by which the tau protein is transformed from a healthy cell component into a driver of crippling diseases is described by researchers at UT Southwestern’s O’Donnell Brain Institute. Their work sheds new light on the underlying mechanism involved in several neurodegenerative disorders, such as Alzheimer’s disease and other…

Treatment with investigational compound BAN2401 over 18 months reduced the accumulation of amyloid fibers in the brain and slowed Alzheimer’s disease progression, according to top-line results from a Phase 2 trial. This follows a previous announcement in December 2017 by Eisai and Biogen, the therapy’s developers, that the treatment had…